At the time of writing, Upstream Bio Inc [UPB] stock is trading at $29.35, down -1.71%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The UPB shares have gain 8.14% over the last week, with a monthly amount glided 17.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Upstream Bio Inc [NASDAQ: UPB] stock has seen the most recent analyst activity on December 18, 2025, when Mizuho initiated its Outperform rating and assigned the stock a price target of $51. Previously, Evercore ISI started tracking the stock with Outperform rating on November 18, 2025, and set its price target to $40. On October 14, 2025, Truist initiated with a Buy rating and assigned a price target of $47 on the stock. William Blair started tracking the stock assigning a Outperform rating. TD Cowen initiated its recommendation with a Buy. Piper Sandler started tracking with a Overweight rating for this stock on November 05, 2024, and assigned it a price target of $75. In a note dated November 05, 2024, JP Morgan initiated an Overweight rating and provided a target price of $38 on this stock.
For the past year, the stock price of Upstream Bio Inc fluctuated between $5.14 and $30.27. Currently, Wall Street analysts expect the stock to reach $49 within the next 12 months. Upstream Bio Inc [NASDAQ: UPB] shares were valued at $29.35 at the most recent close of the market. An investor can expect a potential return of 66.95% based on the average UPB price forecast.
Analyzing the UPB fundamentals
According to Upstream Bio Inc [NASDAQ:UPB], the company’s sales were 2.80M for trailing twelve months, which represents an 12.52% jump. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -44.65%, Pretax Profit Margin comes in at -38.37%, and Net Profit Margin reading is -38.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.36 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.84 points at the first support level, and at 28.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 30.21, and for the 2nd resistance point, it is at 31.07.
Ratios To Look Out For
It is important to note that Upstream Bio Inc [NASDAQ:UPB] has a current ratio of 32.67. Further, the Quick Ratio stands at 32.67, while the Cash Ratio is 4.16. Considering the valuation of this stock, the price to sales ratio is 566.44, the price to book ratio is 4.19.
